卡多尼利马布 (PD-1/CTLA-4双特异抗体) 诱导的输液相关反应:七个病例报告
Weiting Liang1, Zhijun Guo2, Yunhui Zhang1
1Department of Pharmacy, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
卡多尼利马布 (AK104) 是一种PD-1/CTLA-4双特异性抗体,可引起输液相关反应 (IRR). 用药物的预治疗和较慢的输液速度可能有助于预防或减少患者的这些反应.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡多尼利马布 (AK104) 是一种新型双特异性抗体,向编程细胞死亡-1 (PD-1) 和细胞毒性T淋巴细胞抗原-4 (CTLA-4).
- 虽然表现出较低的细胞毒性比联合PD-1和CTLA-4阻塞,cadonilimab与输液相关反应 (IRRs) 有关.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Allergic Drug Reactions
Tumor Immunotherapy
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)